We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Blueberry Therapeutics will use the net proceeds of the Series B Fundraising to fund its development programme for BB2603 for the treatment of onychomycosis and tinea pedis, as well as progressing its earlier stage acne, topical analgesia and atopic derma
Since the introduction of the vaccination against the Human Papilloma Virus in 2008, there has been an 86% drop in the incidence of infection in women aged 16 to 21.
It is rare to hear bad news in the fight against the spread of HIV, with the global campaign against the virus leading to better support, awareness and access to antiretroviral medicines.